NY A02650

Requires insurance carriers and health plans to cover at least one abuse-deterrent opioid analgesic drug product per opioid active ingredient on their formularies

Prohibits prior authorization requirements from mandating patients try non-abuse-deterrent opioids before accessing abuse-deterrent opioid products

Caps cost-sharing for abuse-deterrent opioids at the same level as comparable non-abuse-deterrent opioids (brand name compared to brand name, generic to generic)

Prohibits insurers from increasing patient cost-sharing or creating disincentives for prescribers/dispensers to achieve compliance with these requirements

Takes effect 120 days after becoming law and applies to all policies issued, renewed, or modified after that date